Overview

Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty

Status:
NOT_YET_RECRUITING
Trial end date:
2027-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the incidence of rheumatologic flares, changes in pain scores (VAS), changes in functional outcomes (PROMIS), wound complications, surgical site infections, and return trips to the operating room for rheumatology patients following shoulder replacements, comparing those who stop their immunosuppressants preoperatively for the same amount of time as suggested in the literature for hip and knee arthroplasty versus those who hold the medications for a shorter period of time preoperatively.
Phase:
PHASE2
Details
Lead Sponsor:
NYU Langone Health
Treatments:
Abatacept
Adalimumab
Azathioprine
belimumab
bimekizumab
canakinumab
Certolizumab Pegol
Cyclosporine
Etanercept
golimumab
guselkumab
Hydroxychloroquine
Infliximab
Interleukin 1 Receptor Antagonist Protein
ixekizumab
Leflunomide
Methotrexate
Mycophenolic Acid
risankizumab
Rituximab
secukinumab
Sulfasalazine
Tacrolimus
tocilizumab
tofacitinib
upadacitinib
Ustekinumab